144 related articles for article (PubMed ID: 34712610)
21. Accuracy of High-Field Intraoperative MRI in the Detectability of Residual Tumor in Glioma Grade IV Resections.
Heßelmann V; Mager AK; Goetz C; Detsch O; Theisgen HK; Friese M; Schwindt W; Gottschalk J; Kremer P
Rofo; 2017 Jun; 189(6):519-526. PubMed ID: 28591887
[No Abstract] [Full Text] [Related]
22. Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence.
Ekinci G; Akpinar IN; Baltacioğlu F; Erzen C; Kiliç T; Elmaci I; Pamir N
Eur J Radiol; 2003 Feb; 45(2):99-107. PubMed ID: 12536087
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Johnson BE; Mazor T; Hong C; Barnes M; Aihara K; McLean CY; Fouse SD; Yamamoto S; Ueda H; Tatsuno K; Asthana S; Jalbert LE; Nelson SJ; Bollen AW; Gustafson WC; Charron E; Weiss WA; Smirnov IV; Song JS; Olshen AB; Cha S; Zhao Y; Moore RA; Mungall AJ; Jones SJM; Hirst M; Marra MA; Saito N; Aburatani H; Mukasa A; Berger MS; Chang SM; Taylor BS; Costello JF
Science; 2014 Jan; 343(6167):189-193. PubMed ID: 24336570
[TBL] [Abstract][Full Text] [Related]
24. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
25. Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine.
Im JH; Yoo BC; Lee JH; Kim KH; Kim TH; Lee KY; Kim JH; Park JB; Kwon JW; Shin SH; Yoo H; Gwak HS
EPMA J; 2020 Sep; 11(3):469-484. PubMed ID: 32849928
[TBL] [Abstract][Full Text] [Related]
26. Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003.
Benesch M; Eder HG; Sovinz P; Raith J; Lackner H; Moser A; Urban C
Pediatr Neurosurg; 2006; 42(3):159-64. PubMed ID: 16636617
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.
Daniel P; Sabri S; Chaddad A; Meehan B; Jean-Claude B; Rak J; Abdulkarim BS
Front Oncol; 2019; 9():41. PubMed ID: 30778375
[TBL] [Abstract][Full Text] [Related]
28. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
29. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
30. Surgical management of incidentally discovered diffusely infiltrating low-grade glioma.
Opoku-Darko M; Lang ST; Artindale J; Cairncross JG; Sevick RJ; Kelly JJP
J Neurosurg; 2018 Jul; 129(1):19-26. PubMed ID: 28984519
[TBL] [Abstract][Full Text] [Related]
31. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
32. Expression of enzymes and oncogene induced after radiotherapy and/or chemotherapy in patients with brain tumors.
Yoshii Y; Saito A; Hyodo A; Tsurushima H; Sun L
Hum Cell; 2001 Mar; 14(1):95-103. PubMed ID: 11436358
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
[TBL] [Abstract][Full Text] [Related]
34. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Miller AM; Shah RH; Pentsova EI; Pourmaleki M; Briggs S; Distefano N; Zheng Y; Skakodub A; Mehta SA; Campos C; Hsieh WY; Selcuklu SD; Ling L; Meng F; Jing X; Samoila A; Bale TA; Tsui DWY; Grommes C; Viale A; Souweidane MM; Tabar V; Brennan CW; Reiner AS; Rosenblum M; Panageas KS; DeAngelis LM; Young RJ; Berger MF; Mellinghoff IK
Nature; 2019 Jan; 565(7741):654-658. PubMed ID: 30675060
[TBL] [Abstract][Full Text] [Related]
35. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
[No Abstract] [Full Text] [Related]
36. Longitudinal analysis of treatment-induced genomic alterations in gliomas.
Erson-Omay EZ; Henegariu O; Omay SB; Harmancı AS; Youngblood MW; Mishra-Gorur K; Li J; Özduman K; Carrión-Grant G; Clark VE; Çağlar C; Bakırcıoğlu M; Pamir MN; Tabar V; Vortmeyer AO; Bilguvar K; Yasuno K; DeAngelis LM; Baehring JM; Moliterno J; Günel M
Genome Med; 2017 Feb; 9(1):12. PubMed ID: 28153049
[TBL] [Abstract][Full Text] [Related]
37. Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas.
Fukuya Y; Ikuta S; Maruyama T; Nitta M; Saito T; Tsuzuki S; Chernov M; Kawamata T; Muragaki Y
J Neurooncol; 2019 Sep; 144(3):519-528. PubMed ID: 31363908
[TBL] [Abstract][Full Text] [Related]
38. Flare Phenomenon in
Filss CP; Schmitz AK; Stoffels G; Stegmayr C; Lohmann P; Werner JM; Sabel M; Rapp M; Goldbrunner R; Neumaier B; Mottaghy FM; Shah NJ; Fink GR; Galldiks N; Langen KJ
J Nucl Med; 2020 Sep; 61(9):1294-1299. PubMed ID: 32005771
[TBL] [Abstract][Full Text] [Related]
39. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.
van Meyel DJ; Ramsay DA; Casson AG; Keeney M; Chambers AF; Cairncross JG
J Natl Cancer Inst; 1994 Jul; 86(13):1011-7. PubMed ID: 8007011
[TBL] [Abstract][Full Text] [Related]
40. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
